RGT001-075

DRUG3 trials

Sponsors

Regor Pharmaceuticals Inc.

Conditions

ObesityObesity or OverweightType 2 Diabetes Mellitus

Phase 2

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

TerminatedNCT05297045

Regor Pharmaceuticals Inc.Type 2 Diabetes Mellitus

Start: 2022-03-29End: 2023-05-30Updated: 2023-11-18

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

CompletedNCT06277934

Regor Pharmaceuticals Inc.Obesity

Start: 2024-03-08End: 2024-08-13Updated: 2025-08-07

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

CompletedNCT06867718

Regor Pharmaceuticals Inc.Obesity or Overweight

Start: 2025-01-24End: 2025-11-06Updated: 2026-05-28

Related Papers

785-P: First Report on the Small Molecule Oral GLP-1 Receptor Agonist RGT-075 in Obesity—A Randomized, Placebo-Controlled Phase 2a Proof-of-Concept Twelve-Week Study

Diabetes2025-06-131 citations